Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Gains from Sales and Divestitures (2016 - 2026)

Intellia Therapeutics has reported Gains from Sales and Divestitures over the past 11 years, most recently at $1.5 million for Q1 2026.

  • Quarterly Gains from Sales and Divestitures rose 0.53% to $1.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Mar 2026, up 0.53% year-over-year, with the annual reading at $2.1 million for FY2025, 44.87% up from the prior year.
  • Gains from Sales and Divestitures was $1.5 million for Q1 2026 at Intellia Therapeutics, down from $2.1 million in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $2.1 million in Q4 2025 and troughed at $54666.0 in Q1 2022.
  • The 5-year median for Gains from Sales and Divestitures is $1.0 million (2024), against an average of $946269.9.
  • Year-over-year, Gains from Sales and Divestitures skyrocketed 550.69% in 2023 and then grew 0.53% in 2026.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $147674.0 in 2022, then soared by 358.48% to $677055.0 in 2023, then surged by 111.75% to $1.4 million in 2024, then skyrocketed by 44.87% to $2.1 million in 2025, then dropped by 26.91% to $1.5 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Gains from Sales and Divestitures are $1.5 million (Q1 2026), $2.1 million (Q4 2025), and $1.8 million (Q3 2025).